Downregulation of p27 (cyclin-dependent kinase inhibitor-1B, CDKN1B or KIP1) is caused by increased ubiquitin-mediated proteasomal degradation in colorectal cancer, and has been associated with poor prognosis. CpG island methylator phenotype (CIMP) is a phenotype of colorectal cancer with extensive promoter methylation, and associated with high degree of microsatellite instability (MSI-H) and BRAF mutations. We have recently shown that both CIMP and MSI-H are inversely associated with downregulation of p21 (CDKN1A or CIP1), another cyclin-dependent kinase inhibitor. However, no study to date has examined relationship between p27 and CIMP status in colorectal cancer. Using MethyLight assays, we measured DNA methylation in five CIMP-specific gene promoters {CACNA1G, CDKN2A (p16), CRABP1, MLH1 and NEUROG1} in 706 colorectal cancer samples obtained from two large prospective cohorts. Among the 706 tumors, 112 (16%) were CIMP-high tumors with Z4/5 methylated promoters. We assessed p27 and p53 expressions by immunohistochemistry. Loss of nuclear p27 expression {observed in 231 tumors (33%)} was significantly associated with CIMP-high, MSI-H and BRAF mutations, and these associations were much more pronounced among p53-negative tumors than p53-positive tumors. When CIMP-high and non-CIMP-high tumors were stratified by MSI status (or KRAS and BRAF status), CIMP-high and MSI-H (but not BRAF mutations) were still significantly associated with nuclear p27 loss. Nuclear p27 loss did not appear to be directly related to CDKN2A (p16) methylation. We conclude that downregulation of nuclear p27 is associated with CIMP-high and MSI-H in colorectal cancer. These associations are stronger among p53 wild-type tumors, implying important interplay of p27 and p53 functions (or dysfunctions) in the development of various molecular subtypes of colorectal cancer. Modern Pathology (2007) 20, 15-22.
Progression through the cell cycle involves sequential activation and inactivation of cyclin-dependent kinases (CDKs). 1 CDKs are activated through association with positive regulators (cyclins) and inactivated by cyclin-CDK inhibitors. p27 (cyclindependent kinase inhibitor 1B, CDKN1B or KIP1) is one of the cyclin-CDK inhibitors and plays a key role in preventing progression into S-phase of the cell cycle. 1 Regulation of p27 levels is achieved post-translationally through ubiquitin-mediated protein degradation. 2 The F-box protein SKP2 has been identified as the substrate recognition component that binds and targets p27 for ubiquitination and subsequent degradation. 3, 4 Low levels of p27 have been associated with tumor progression and poor prognosis in various cancers including colon, breast and prostate cancers. [5] [6] [7] [8] Although mutations or deletions of p27 allele rarely occur, downregulation of p27 in colorectal cancer mainly result from abnormal activation of ubiquitin-mediated proteolysis. 5, 6 CDKN1B (p27) promoter has not been shown to be significantly methylated in colorectal cancer. 9 Transcriptional inactivation by cytosine methylation at promoter CpG islands of tumor suppressor genes is thought to be an important mechanism in human carcinogenesis. 10, 11 A number of tumor suppressor genes, including CDKN2A (p16/INK4A), MGMT, MLH1, etc., are silenced by promoter methylation in colorectal cancer. 10, 11 A subset of colorectal cancers exhibit promoter methylation in multiple genes, referred to as the CpG island methylator phenotype (CIMP). 10, 12, 13 CIMP-positive colorectal tumors appear to have a distinct clinical, pathologic and molecular profile, including associations with female sex, proximal tumor location, mucinous and poor differentiations, microsatellite instability (MSI) and BRAF mutations.
12,14-20 A recent report suggests a possible association between JC virus and CIMP in colorectal cancer. 21 We have recently demonstrated that both MSI and CIMP are inversely associated with downregulation of p21 (CDKN1B/KIP1), another cyclin-dependent kinase inhibitor. 22 However, no study to date has examined relationship between p27 expression and CIMP. In addition, previous studies have not shown any correlation for p27 expression with MSI status 23 or mutations in the TGFBR2 gene (encoding TGF-b receptor type II) within MSI-H tumors. 24 In this study, using quantitative real-time PCR (MethyLight) assays, 19, [25] [26] [27] and population-based samples of colorectal cancer from two large prospective cohort studies, we have shown correlations of loss of nuclear p27 expression with CIMP and MSI. MethyLight assays can reliably distinguish high from low levels of DNA methylation, the latter of which likely have little or no biological significance. 28 
Materials and methods

Study Group
We utilized the databases of two large prospective cohort studies; the Nurses' Health Study (N ¼ 121 700 women followed since 1976), 29 and the Health Professional Follow-up Study (N ¼ 51 500 men followed since 1986). 30 Informed consent was obtained from all participants before inclusion in the cohorts. All cohort participants were free of cancer (except for nonmelanoma skin cancer) at the time of study entry. A subset of the cohort participants developed colorectal cancers during prospective follow-up. We included cases only if there was adequate paraffin-embedded tumor tissue and results were available for DNA methylation and p27 at the time of this study. As a result, a total of 706 colorectal cancer cases (316 from the men's cohort and 390 from the women's cohort) were included in this study. Most cases have been previously characterized for status of CIMP, MSI, KRAS, BRAF and p53. 19, 22, 31 However, no tumor has previously been studied for p27. Tissue collection and analyses were approved by the Institutional Review Boards.
MSI Analysis
Genomic DNA was extracted as previously described. 32 Whole genome amplification (WGA) of genomic DNA was performed by PCR using random 15-mer primers. 33 Methods for MSI analysis were previously described. 34 In addition to D2S123, D5S346, D17S250, BAT25 and BAT26 (the NCI panel), we used BAT40, D18S55, D18S56, D18S67 and D18S487 (ie, a 10-marker panel). 'MSI-high (MSI-H)' was defined as instability in 30% or more of the markers, 'MSI-low (MSI-L)' as instability in o30% of the markers, and 'microsatellite stability (MSS)' as no unstable marker.
Quantitative Real-Time PCR for DNA Methylation (MethyLight) Sodium bisulfite treatment on genomic DNA was performed as previously described. 28 Real-time PCR to measure DNA methylation (MethyLight) was performed as previously described. [25] [26] [27] We used ABI 7300 (Applied Biosystems, Foster City, CA, USA) for quantitative real-time PCR on five CIMPspecific promoters (CACNA1G, CDKN2A (p16/ INK4A), CRABP1, MLH1 and NEUROG1). 19 We have previously validated the selection and use of these five markers as a CIMP-specific promoter panel.
19
COL2A1 (the collagen 2A1 gene) was used to normalize for the amount of input bisulfite-converted DNA. 27, 28 Primers and probes were previously described: CACNA1G, CRABP1 and NEUROG1;
CDKN2A and COL2A1; 27 and MLH1. 28 Percentage of methylated reference (PMR) was determined in each locus, and methylation positivity was defined as PMR Z4 (or Z6 for CRABP1) as previously validated. [26] [27] [28] 35 Precision and performance characteristics of bisulfite conversion and subsequent MethyLight assays have been previously evaluated and the assays have been validated. 28 The CpG island methylator phenotype-high (CIMP-high) was defined as the presence of Z4/5 methylated promoters. 19 CIMP-low was defined as the presence of 1/5-3/5 methylated promoters, and CIMP-0 was defined as the absence of methylation in any of the five promoters. 36 Sequencing of KRAS and BRAF PCR and sequencing targeted for KRAS codons 12 and 13 and BRAF codon 600 have been performed as previously described. 33, 37 TMA and Immunohistochemistry for p27 and p53
Tissue microarrays (TMAs) were constructed for p53 analysis as previously described, 31 using the Automated Arrayer (Beecher Instruments, Sun Prairie, WI, USA).
Methods for p27 immunohistochemistry were previously described. 37 The extent of nuclear p27 expression was visually estimated using whole tissue sections, and interpreted as 'loss' (no staining, For p53 immunohistochemistry, deparaffinized tissue sections in a citrate buffer (BioGenex, San Ramon, CA, USA) were microwaved in a pressure cooker at high power for 15 min. Tissue sections were incubated with 3% H 2 O 2 (10 min) to block endogenous peroxidase, and then incubated with protein block (Vector Laboratories, Burlingame, CA, USA) (10 min). Primary anti-p53 mouse monoclonal antibody (clone DO-1, Calbiochem, San Diego, CA, USA) (dilution 1:50) was applied for 30 min at room temperature. Then, biotinylated secondary MultiLink antibody (Biogenex) was applied (20 min), horse radish peroxidase avidin complex (Biogenex) was added (20 min) and sections were visualized by DAB (5 min) and methyl-green counterstain. We visually estimated the fraction of tumor cells with strong and unequivocal nuclear staining for p53, by examining at least two tissue cores in TMAs, or the whole tissue section in each case for which there was not enough tissue for TMAs or results were equivocal in TMAs. p53 positivity was defined as 50% or more of tumor cells with unequivocal strong nuclear staining.
Appropriate positive and negative controls were included in each run of p27 and p53 immunohistochemistry. All immunohistochemically stained slides were interpreted by a pathologist (SO) blinded from any other laboratory data.
Statistical Analysis
In statistical analysis, w 2 test (or Fisher's exact test when the number of cases in any category was o10) was performed for categorical data, using the SAS program (version 9.1, SAS Institute, Cary, NC, USA). All P-values were two-sided, and statistical significance was set at Pr0.05.
Results
Loss of p27 is Correlated with MSI and CIMP
We examined p27 expression in 706 colorectal cancer specimens by immunohistochemistry, with 231 tumors (33%) showing p27 loss. We also quantified DNA methylation in a panel of the five CIMP-specific promoters (CACNA1G, CDKN2A, CRABP1, MLH1 and NEUROG1) 19 by MethyLight, with 112 tumors (16%) classified as CIMP-high (Z4/5 methylated promoters). We have previously validated the selection and use of these five markers for the determination of CIMP status. 19 Colorectal cancers with p27 loss showed a significantly higher frequency of CIMP-high (27%) than p27 1 þ tumors (7.0%, Po0.0001) and than p27 2 þ tumors (16%, P ¼ 0.02) ( Table 1) . With regard to p27 and MSI status, colorectal cancers with p27 loss showed a significantly higher frequency of MSI-H (26% ¼ 60/231) than p27 1 þ tumors (9.9% ¼ 28/283, Po0.0001) and p27 2 þ tumors (14% ¼ 17/120, P ¼ 0.01).
In order to determine whether the association of p27 loss with CIMP-high was due to methylation of CDKN2A (p16, another important cell cycle regulator) rather than CIMP-high, we examined the frequencies of p27 loss among CIMP-high and CIMP-low/0 tumors stratified by CDKN2A methylation status (Supplementary Material). For this analysis, CDKN2A was excluded from the CIMP panel to avoid its confounding effect on diagnosing CIMP status, and CIMP-high was defined as the presence of Z3/4 methylated promoters. The fre- CIMP, MSI and p27 in colorectal cancer S Ogino et al quencies of p27 loss were higher among CIMP-high tumors than CIMP-low/0 even after tumors were stratified by CDKN2A methylation status. In contrast, after stratification by CIMP status, CDKN2A-methylated and unmethylated tumors did not show a significant difference in the frequencies of p27 loss. Therefore, p27 loss was associated primarily with CIMP-high, rather than CDKN2A methylation.
Combined p27/p53 Status, CIMP and MSI As a result of important roles of both p27 and p53 in regulating the cell cycle, we correlated combined status of p27 and p53 with CIMP and MSI. The association of p27 loss with CIMP-high or MSI-H was much more pronounced among p53-negative tumors than p53-positive tumors ( Table 2 ). For instance, p53-negative/p27-loss tumors showed significantly higher frequencies of CIMP-high and MSI-H than p53-negative/p27 1 þ tumors and than p53-negative/p27 2 þ tumors ( Table 2 ). In contrast, there was no significant difference in CIMP-high or MSI-H frequencies among p53-positive tumor groups.
Combined p27/p53 Status, and KRAS/BRAF Mutations
We correlated combined status of p27 and p53 with KRAS and BRAF mutations (Table 3 ). p53-negative/ p27-loss tumors showed a significantly higher frequency of BRAF mutations (28%) than p53-negative/p27 1 þ tumors (8.9%, P ¼ 0.0003) and p53-negative/p27 2 þ tumors (15%, P ¼ 0.04) ( Table  3 ). In contrast, there was no significant difference in the frequencies of BRAF mutations among p53-positive tumor groups. 
p27 Loss in Various CIMP/KRAS/BRAF Subtypes of Colorectal Cancer
In order to examine an association between p27 loss and KRAS/BRAF mutations independent of CIMP status, we examined the frequencies of p27 loss in six subtypes of colorectal cancer according to combined status of CIMP/KRAS/BRAF (Figure 4) . Among CIMP-low/0 tumors, CIMP-low/0 BRAFmutated tumors showed a higher frequency of p27 loss (46% ¼ 13/28) than CIMP-low/0 KRAS/BRAF wild-type tumors (26% ¼ 83/316, P ¼ 0.02) ( Figure  4 ). In particular, among CIMP-low tumors, p27 loss was significantly more common in CIMP-low BRAFmutated (KRAS wild-type) tumors (55% ¼ 11/20) than CIMP-low KRAS/BRAF wild-type tumors (30% ¼ 29/98, P ¼ 0.04). However, no association between p27 loss and BRAF mutations was observed among CIMP-high and CIMP-0 tumors. Thus, p27 loss was associated with BRAF mutations only among CIMP-low tumors.
Discussion
We conducted this study to evaluate relationship between downregulation of p27 and well-characterized molecular features of colorectal cancer, including CIMP, MSI and mutations in the KRAS and BRAF oncogenes. We have demonstrated that there were positive correlations for loss of nuclear p27 expression with CIMP-high and MSI-high (MSI-H) in colorectal cancer. Our results are in contrast to a study by Edmonston et al 23 who found no association between p27 loss and MSI. In addition, we have shown that p27 1 þ tumors showed lower frequencies of CIMP-high, MSI-H and BRAF mutations, compared to p27-lost tumors and p27 2 þ tumors. Further studies are necessary to determine whether p27 1 þ tumors are biologically distinct from p27 2 þ tumors.
As CIMP-high and MSI-H (as well as CIMP-high and BRAF mutations) are tightly associated with each other, [16] [17] [18] [19] we stratified tumors according to CIMP and MSI status, and according to CIMP and KRAS/BRAF gene status. The association of p27 loss with CIMP-high (or MSI-H) appeared to be independent of MSI (or CIMP) status. In addition, the association of p27 loss with CIMP-high also appeared to be independent of BRAF status. However, the association of p27 loss with BRAF mutations appeared to be secondary to the associations between BRAF mutations and CIMP-high and between CIMP-high and p27 loss. It is conceivable that a small number of CIMP-high tumors might have been classified as CIMP-low by our strict criteria for CIMP-high (ie, Z4/5 methylated promo- CIMP, MSI and p27 in colorectal cancer S Ogino et al ters), although we have validated our CIMP-high criteria and tumors with 1/5-3/5 methylated promoters have a much higher KRAS mutation rate than tumors with Z4/5 methylated promoters. 19, 36 Therefore, we conclude that p27 loss is associated primarily with CIMP-high and MSI-H, but not with BRAF mutations. We utilized quantitative real-time PCR (MethyLight) to distinguish high from low levels of DNA methylation. Assays to measure DNA methylation may be potentially very useful in clinical practice. 10 DNA methylation may be a useful marker for predicting prognosis and monitoring efficacy of adjuvant therapy in cancer patients 38 and for risk assessment in surveillance of high-or low-risk individuals. 39, 40 In the current study, the use of quantitative DNA methylation assays as well as relatively unbiased, population-based samples of colorectal cancer from two large prospective cohorts has enabled us to precisely estimate the frequency of colorectal cancers with specific molecular features (such as CIMP-high, MSI-H, p27 loss, etc.) at a population level.
As a result of important roles of both p27 and p53 in regulating the cell cycle, we examined whether p53 status in colorectal cancer might modify molecular characteristics of p27-lost or p27-expressed tumors. Interestingly, the associations of p27 loss with CIMP-high, MSI-H and BRAF mutations were much more pronounced among p53-negative (presumably wild-type) tumors than p53-positive (presumably mutated) tumors. Our results imply that functional status of p27 may be much more important in p53 wild-type tumors than p53-mutated tumors. Although p53 immunohistochemistry has been shown to have both false positives and false negatives for the assessment of TP53 gene mutations, when higher threshold of p53 positivity is used (as in the current study), p53 immunohistochemistry can generally predict the presence or absence of mutations of the TP53 gene. [41] [42] [43] We have recently demonstrated inverse associations of CIMP-high and MSI-H with downregulation of p21 (CDKN1A/CIP1), another important cyclindependent kinase inhibitor. 22 Taken together with our current results, CIMP-high MSI-H tumors tend to downregulate p27, whereas non-CIMP non-MSI tumors tend to downregulate p21. Further studies are necessary to elucidate exact pathogenetic links between CIMP/MSI and p27 downregulation, and between non-CIMP/non-MSI and p21 downregulation.
Our data may have significant clinical implications because of emerging importance of both DNA methylation and the ubiquitin-proteasome pathway as attractive chemotherapeutic/chemopreventive targets. 6, 10 The mechanisms of p27 regulation are shown to be at the post-translational level and, in particular, the ubiquitin-proteasome pathway plays an important role in downregulation of p27 in aggressive colorectal cancer. 5, 8 Our data might suggest that targeting both epigenetic alterations and the ubiquitin pathway might be effective against tumors with CIMP-high and/or MSI-H. In addition, for therapeutic approaches targeting p27 and/or the ubiquitin pathway, it is likely important to consider the effects of mutant or wild-type p53, potentially modulating the signaling pathway downstream of p27. Elucidating the molecular link between CIMP and p27 downregulation may be important for the purpose of developing molecularly targeted treatment against CIMP-high colorectal cancer. In addition, elucidating mechanisms that may overcome the tumor suppressor function of p27 in CIMP-low/0 tumors may also be important for the development of targeted therapy against CIMP-low/0 tumors.
The prognostic significance of p27 loss has been examined in previous studies, which have shown that p27 loss was a significant predictor of worse survival by multivariate analysis. 5, 44, 45 Manne et al 46 examined p27 expression in colorectal cancer stratified by stage and found that p27 loss was associated with local recurrence and poor survival only for stage III colorectal cancer. The authors also found that p27 loss was associated with poor differentiation (in stage II tumors) and distal location. 46 In contrast, Palmqvist et al 44 showed that p27 loss was associated with proximal location. These discrepant results may be attributable to differences in patient populations and criteria of p27 interpretation. The prognostic significance of CIMP or MSI stratified by the status of p27 has not been studied. Our prospective cohort studies, the Nurses' Health Study (N ¼ 120 000, followed since 1976) 29 and the Health Professional Follow-up Study (N ¼ 51 000, followed since 1986), 30 are currently ongoing, and thus, relational data on patient survival and CIMP or MSI status stratified by p27 status will be available in the future.
In conclusion, loss of nuclear p27 in colorectal cancer is associated with CIMP-high and MSI-H, and these associations are much more pronounced in p53 wild-type tumors. Our results imply that there is interplay of p27 and p53 function (or dysfunction) in the development of various molecular subtypes of colorectal cancer. Exact biological significance of p27 loss and effects of p53, CIMP and MSI status need further investigations.
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